These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32146090)

  • 21. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
    Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
    Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
    Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
    Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does the dose matter? Antiproliferative efficacy and toxicity of everolimus in patients with neuroendocrine tumors - Experiences from a tertiary referral center.
    Kiesewetter B; Melhorn P; Macheiner S; Wolff L; Kretschmer-Chott E; Haug A; Mazal P; Raderer M
    J Neuroendocrinol; 2023 Aug; 35(8):e13319. PubMed ID: 37485760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors.
    Caruso D; Polici M; Rinzivillo M; Zerunian M; Nacci I; Marasco M; Magi L; Tarallo M; Gargiulo S; Iannicelli E; Annibale B; Laghi A; Panzuto F
    Radiol Med; 2022 Jul; 127(7):691-701. PubMed ID: 35717429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer.
    Medairos RA; Clark J; Holoubek S; Kubasiak JC; Pithadia R; Hamid F; Chmielewski GW; Warren WH; Basu S; Borgia JA; Liptay MJ; Seder CW
    J Thorac Cardiovasc Surg; 2016 Jul; 152(1):55-61.e1. PubMed ID: 27157918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
    Jacobi O; Landman Y; Reinhorn D; Icht O; Sternschuss M; Rotem O; Finkel I; Allen AM; Dudnik E; Goldstein DA; Zer A
    Oncology; 2021; 99(9):555-561. PubMed ID: 34247166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.
    Pusceddu S; Corti F; Prinzi N; Nichetti F; Ljevar S; Busico A; Cascella T; Leporati R; Oldani S; Pircher CC; Coppa J; Resi V; Milione M; Maccauro M; Miceli R; Tamborini E; Perrone F; Spreafico C; Niger M; Morano F; Pietrantonio F; Seregni E; Mariani L; Mazzaferro V; Di Liberti G; Fucà G; de Braud F; Vernieri C
    J Hematol Oncol; 2023 Dec; 16(1):119. PubMed ID: 38098114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments.
    Angelousi A; Kamp K; Kaltsatou M; O'Toole D; Kaltsas G; de Herder W
    Neuroendocrinology; 2017; 105(4):394-402. PubMed ID: 28122378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
    Yao JC; Pavel M; Lombard-Bohas C; Van Cutsem E; Voi M; Brandt U; He W; Chen D; Capdevila J; de Vries EGE; Tomassetti P; Hobday T; Pommier R; Öberg K
    J Clin Oncol; 2016 Nov; 34(32):3906-3913. PubMed ID: 27621394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of
    Medaer E; Verslype C; Van Cutsem E; Dekervel J; Clement PM; Nackaerts K; Laenen A; Gheysens O; Goffin K; Jentjens S; Van Laere K; Deroose CM
    Acta Oncol; 2020 Jun; 59(6):644-651. PubMed ID: 32036716
    [No Abstract]   [Full Text] [Related]  

  • 31. Role of everolimus in the treatment of advanced neuroendocrine tumor: a meta-analysis of randomized trials.
    Zhuo ZG; Zhu YK; Deng HY; Li G; Luo J; Alai GH; Lin YD
    J BUON; 2019; 24(1):368-373. PubMed ID: 30941993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
    Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
    Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).
    Vernieri C; Pusceddu S; Fucà G; Indelicato P; Centonze G; Castagnoli L; Ferrari E; Ajazi A; Pupa S; Casola S; Foiani M; Mazzaferro V; Pruneri G; Milione M; de Braud F
    Int J Cancer; 2019 Apr; 144(7):1704-1712. PubMed ID: 30520016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Everolimus in ileum neuroendocrine tumours.
    Walter T; Lombard-Bohas C
    Lancet; 2016 Jul; 388(10041):236. PubMed ID: 27479567
    [No Abstract]   [Full Text] [Related]  

  • 35. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
    Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
    Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Universal everolimus for malignant neuroendocrine tumours?
    Öberg K
    Lancet; 2016 Mar; 387(10022):924-926. PubMed ID: 26703890
    [No Abstract]   [Full Text] [Related]  

  • 37. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.
    Flaum N; Valle JW; Mansoor W; McNamara MG
    Future Oncol; 2016 Nov; 12(22):2561-2578. PubMed ID: 27412069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
    Fazio N; Buzzoni R; Baudin E; Antonuzzo L; Hubner RA; Lahner H; DE Herder WW; Raderer M; Teulé A; Capdevila J; Libutti SK; Kulke MH; Shah M; Dey D; Turri S; Aimone P; Massacesi C; Verslype C
    Anticancer Res; 2016 Feb; 36(2):713-9. PubMed ID: 26851029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Everolimus in ileum neuroendocrine tumours - Authors' reply.
    Yao JC; Voi M; Rouyrre N; Singh S
    Lancet; 2016 Jul; 388(10041):236-7. PubMed ID: 27479568
    [No Abstract]   [Full Text] [Related]  

  • 40. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
    Kulke MH; Ruszniewski P; Van Cutsem E; Lombard-Bohas C; Valle JW; De Herder WW; Pavel M; Degtyarev E; Brase JC; Bubuteishvili-Pacaud L; Voi M; Salazar R; Borbath I; Fazio N; Smith D; Capdevila J; Riechelmann RP; Yao JC
    Ann Oncol; 2017 Jun; 28(6):1309-1315. PubMed ID: 28327907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.